| Outcome Measures: |
Primary: Change in measured GFR, GFR will be determined from the average of creatinine and urea clearance from a 24-hour urine collection., Before and 2 weeks after initiation of empagliflozin. | Secondary: Rebound in GFR after Cessation of Therapy, A GFR measurement will be performed 2 weeks after cessation of empagliflozin, with the aim of capturing the reversible "rebound" in GFR after cessation of therapy., 2 weeks|Change in ultrafiltration volume, 2 weeks|Change in fraction of glucose remaining in the dialysate, 2 weeks|Change in dialysate/plasma creatinine, 2 weeks|Change in dialysate/plasma urea, 2 weeks|Change in sodium dialysate concentration, 2 weeks|Change in glycated hemoglobin (HbA1c), 2 weeks|Change in systolic and diastolic blood pressure, 2 weeks|Change in body weight, 2 weeks|Change in body composition (percent body mass, body fat, and muscle mass), Bioimpedence measurements will be taken to study the effects of intervention on body composition., 2 weeks|Change in fractional urine excretion of sodium, Urinary analysis will be performed to quantify the amount of sodium excretion., 2 weeks|Change in fractional urine excretion of glucose, Urinary analysis will be performed to quantify the amount of glucose excretion., 2 weeks|Change in eGFRβ2-microglobulin, Blood sample analysis to assess middle molecule clearance., 2 weeks|Change in degree of albuminuria, Urinary analysis will be performed to determine if there has been any change in the severity of albuminuria, 2 weeks|Change in BNP (NT-proB-type Natriuretic Peptide), 2 weeks|Change in markers of neurohumoral activation, erythropoiesis, and inflammation., 2 weeks|The safety of empaglifllozin use in PD patients with RKF with regard to anuria (<100cc/day), volume depletion, diabetic ketoacidosis, genito-urinary infections, PD peritonitis and death will be evaluated., 2 weeks
|
